Literature DB >> 11932168

Evolution of allograft aortic valve replacement over 13 years: results of 275 procedures.

J J M Takkenberg1, L A van Herwerden, M J C Eijkemans, J A Bekkers, A J J C Bogers.   

Abstract

OBJECTIVE: We describe our center's experience with the use of allografts for aortic valve or root replacement, illustrating the impact on outcome of the changes made in surgical and preservation techniques.
METHODS: Between 4/1987 and 1/2001 275 allografts were used in 267 consecutive patients to replace the aortic valve or root. All patients were prospectively followed over time. Mean patient age was 46 years (SD 16; range 0.06-83), male/female ratio was 201/74. Prior cardiac operations took place in 73 patients; 49 patients presented with active endocarditis. Pre-operative NYHA-class was III in 51%. Initially, the subcoronary technique was used (SC; N=95) while in recent years root replacement (ARR; N=180) became the technique of choice. Seven fresh (two pulmonary and five aortic) and 268 cryopreserved (four pulmonary and 264 aortic; 35 glycerol and 233 DMSO) allografts were implanted. Concomitant procedures took place in 133 (48%).
RESULTS: Operative mortality was 5.5% (N=15) and during follow-up (99% complete) 29 more patients died. Overall cumulative survival was 73% (95% CI 65-81%) at 9 years postoperative and significantly better for SC compared to ARR patients (P=0.005). Freedom from allograft-related reoperation (N=34) was 77% (95% CI 69-85) at 9 years, and worse in the SC compared to ARR group due to increased early technical failure (P=0.03). Freedom from reoperation for structural valve deterioration (SVD; N=22) was 81% (95% CI 73-89) at 9 years and did not differ between SC and ARR (P=0.51). Independent predictors of degenerative SVD were younger patient age (HR 0.93 with age as continuous variable; 95% CI 0.90-0.97), older donor age (HR 1.06 with age as a continuous variable; 95% CI 1.00-1.11), larger allograft diameter (HR 1.38; 95% CI 1.11-1.71) and the use of pulmonary allografts (HR 10.72; 95% CI 3.88-29.63). Calculated median time to reoperation for structural valve deterioration ranged from 23 years in a 65-year-old patient to 12 years in a 25-year-old.
CONCLUSIONS: Aortic valve replacement with allografts yields adequate midterm results. Although important changes have been made over the years to improve durability, allografts still have a limited life span especially in young patients.

Entities:  

Mesh:

Year:  2002        PMID: 11932168     DOI: 10.1016/s1010-7940(02)00025-8

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Fixation of Bovine Pericardium-Based Tissue Biomaterial with Irreversible Chemistry Improves Biochemical and Biomechanical Properties.

Authors:  H Tam; W Zhang; D Infante; N Parchment; M Sacks; N Vyavahare
Journal:  J Cardiovasc Transl Res       Date:  2017-02-17       Impact factor: 4.132

Review 2.  Clinical Application of Bioprosthesis in China: Current Status and Future.

Authors:  Yin Wang; Wei-Wei Jiang; Nian-Guo Dong
Journal:  Curr Med Sci       Date:  2019-07-25

3.  A novel crosslinking method for improved tear resistance and biocompatibility of tissue based biomaterials.

Authors:  Hobey Tam; Will Zhang; Kristen R Feaver; Nathaniel Parchment; Michael S Sacks; Naren Vyavahare
Journal:  Biomaterials       Date:  2015-07-14       Impact factor: 12.479

4.  Arterial switch operation using aortic homograft for transposition of the great arteries with pulmonary regurgitation.

Authors:  Naoki Wada; Yukihiro Takahashi; Makoto Ando; In-Sam Park; Mariko Kobayashi; Masamitsu Murata
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2006-03

5.  Comparison of the function and structural integrity of cryopreserved pulmonary homografts versus decellularized pulmonary homografts after 180 days implantation in the juvenile ovine model.

Authors:  Johannes Jacobus van den Heever; Christiaan Johannes Jordaan; Angelique Lewies; Dreyer Bester; Jacqueline Goedhals; Lezelle Botes; Pascal Maria Dohmen; Francis Edwin Smit
Journal:  Cell Tissue Bank       Date:  2021-08-28       Impact factor: 1.522

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.